4530.T Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 09:15):

Stats
Šios dienos apimtis	323 000
Vidutinė apimtis	173 869
Rinkos kapitalizacija	283.28B
EPS	¥0 ( 2024-04-10 )
Kita pelno data	( ¥0 ) 2024-07-11
Last Dividend	¥42.50 ( 2023-08-30 )
Next Dividend	¥0 ( N/A )
P/E	20.30
ATR14	¥1.655 (0.04%)

Tūris Koreliacija

Ilgas: -0.37 (neutral)

Trumpas: -0.98 (very strong negative)

Signal:(18.22) Possible Trading Opportunity Present (swing)

Hisamitsu Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Hisamitsu Pharmaceutical Koreliacija - Valiuta/Žaliavos

0.03
( neutral )

-0.45
( neutral )

0.91
( very strong )

-0.22
( neutral )

-0.03
( neutral )

0.16
( neutral )

Hisamitsu Pharmaceutical Finansinės ataskaitos

Annual	2023
Pajamos:	¥141.71B
Bruto pelnas:	¥78.97B (55.73 %)
EPS:	¥181.62

FY	2023
Pajamos:	¥141.71B
Bruto pelnas:	¥78.97B (55.73 %)
EPS:	¥181.62

FY	2022
Pajamos:	¥128.33B
Bruto pelnas:	¥72.70B (56.65 %)
EPS:	¥148.00

FY	2022
Pajamos:	¥120.19B
Bruto pelnas:	¥70.07B (58.30 %)
EPS:	¥118.92

Financial Reports:

No articles found.

Hisamitsu Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0.250 (N/A)	¥0 (N/A)	¥0.250 (N/A)	¥0 (N/A)	¥42.50 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Hisamitsu Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.60 - Stable (8.07%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥7.00	2001-02-23
Last Dividend	¥42.50	2023-08-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	42	--
Total Paid Out	¥1 175.50	--
Avg. Dividend % Per Year	0.00%	--
Score	3.73	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.60
Div. Directional Score	7.69	--

Next Divdend (Est)
(2024-09-05)

¥0 Estimate 7.25 %

Dividend Stability

0.29 Very Poor

Dividend Score

3.73

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
7723.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6882.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6255.T	Ex Dividend Junior	2023-08-30	Sporadic	0.00%
4972.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
4185.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
3382.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%
2453.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9386.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
8065.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7337.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0986	1.500	8.03	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0425	1.200	8.58	10.00	[0 - 0.3]
returnOnEquityTTM	0.0524	1.500	-0.529	-0.793	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.22	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.66	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.45	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00455	-1.500	9.92	-10.00	[0 - 0.6]
interestCoverageTTM	731.56	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	96.01	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	96.01	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00565	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.557	1.000	4.05	4.05	[0.2 - 0.8]
operatingProfitMarginTTM	0.0929	1.000	-0.142	-0.142	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.86	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.431	0.800	-0.460	-0.368	[0.5 - 2]
Total Score				10.77

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	20.52	1.000	8.03	0	[1 - 100]
returnOnEquityTTM	0.0524	2.50	-0.340	-0.793	[0.1 - 1.5]
freeCashFlowPerShareTTM	96.01	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.25	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	96.01	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.903	1.500	7.31	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0514	1.000	-1.216	0	[0.1 - 0.5]
Total Score				4.60

Hisamitsu Pharmaceutical

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.